AUROPHARMANSEAUROBINDO PHARMA LTD· Pharmaceuticals & BiotechnologyCriticalNegative

Announced Fri, 14 Aug, 2026 · 09:38 IST

US FDA issues Warning Letter to Aurobindo Pharma subsidiary's Unit I

Regulatory & Legal View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹1663.40

prior close

₹1665.60

announcement price

In-mkt

timing

Nifty Midcap 150market-0.5%-2.0% vs market

Pharmaceuticals peers, median of 166sector-0.4%-2.1% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Midcap 150 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-2.0

15m

-2.1

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5-0.5-2.0-0.4-2.1

Next day

-2.2-0.4-1.8-0.3-1.8

-1.1-0.7-0.4-0.5-0.6

-2.3-1.0-1.3-1.3-1.0

-3.3-0.6-2.7-0.8-2.5

-2.5-0.6-2.0-0.4-2.2

-2.7-0.0-2.7-0.9-1.9

15d

-0.7-1.6+0.9+0.0-0.7

-0.2-5.0+4.8-0.1-0.1

-0.0-7.3+7.3-2.8+2.8

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma's wholly owned subsidiary Eugia Pharma Specialities' Unit I has received a Warning Letter from the US FDA, following an earlier Official Action Indicated (OAI) status flagged in May 2026. The company clarified there is no impact on existing supplies to US markets. Unit I contributes about 2 percent to the company's overall group revenue. The company said it will work closely with the US FDA to enhance compliance.

Likely market impact

Limited near-term impact since the unit is only 2 percent of revenue and US supplies continue, but the Warning Letter may weigh on sentiment and future approvals.